307 related articles for article (PubMed ID: 30286662)
1. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Bhowmik D; Song X; Intorcia M; Gray S; Shi N
Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
3. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
6. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Wang Z; Qiao D; Lu Y; Curtis D; Wen X; Yao Y; Zhao H
Oncologist; 2015 Apr; 20(4):440-9. PubMed ID: 25732263
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
[TBL] [Abstract][Full Text] [Related]
8. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
10. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events.
Hardtstock F; Kocaata Z; Wilke T; Dittmar A; Ghiani M; Belozeroff V; Harrison DJ; Maywald U; Tesch H
Eur J Health Econ; 2021 Mar; 22(2):243-254. PubMed ID: 33459901
[TBL] [Abstract][Full Text] [Related]
12. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Snedecor SJ; Carter JA; Kaura S; Botteman MF
Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
[TBL] [Abstract][Full Text] [Related]
14. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
Barlev A; Song X; Ivanov B; Setty V; Chung K
J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
[TBL] [Abstract][Full Text] [Related]
15. Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study.
Mizuta K; Oshiro H; Katsuki R; Tsuha Y; Aoki Y; Tome Y; Nishida K
BMC Cancer; 2023 Oct; 23(1):999. PubMed ID: 37853409
[TBL] [Abstract][Full Text] [Related]
16. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
von Moos R; Body JJ; Egerdie B; Stopeck A; Brown J; Fallowfield L; Patrick DL; Cleeland C; Damyanov D; Palazzo FS; Marx G; Zhou Y; Braun A; Balakumaran A; Qian Y
Support Care Cancer; 2016 Mar; 24(3):1327-37. PubMed ID: 26329397
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
18. Analysis of denosumab on skeletal-related events in patients with advanced breast cancer.
Bink KF
Clin J Oncol Nurs; 2015 Oct; 19(5):E108-14. PubMed ID: 26414586
[TBL] [Abstract][Full Text] [Related]
19. Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events.
Yaldo A; Wen L; Ogbonnaya A; Valderrama A; Kish J; Eaddy M; Kreilick C; Tangirala K; Shields K
Clin Ther; 2016 Aug; 38(8):1880-9. PubMed ID: 27478111
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients.
Zhong Y; Valderrama A; Yao J; Donga P; Bilir P; Neumann PJ
Value Health; 2018 Mar; 21(3):304-309. PubMed ID: 29566837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]